RB1 and breast cancer: Interestingly, the RB-deficient TNBC cell line MDA-MB-468 showed no synergistic effect of the CDK4/6 inhibition with chemotherapeutic treatments whereas the (non-TNBC) ER + PR + BC cell line, MCF7, did (Sup.